Previous 10 |
Yumanity Therapeutics (YMTX): FY GAAP EPS of -$21.57.Revenue of $6.9MShares +1.43%.Press Release For further details see: Yumanity Therapeutics reports FY results
Closed $33.6 million PIPE in conjunction with the completion of reverse merger with Proteostasis Therapeutics; commenced trading on the Nasdaq Capital Market under the ticker symbol “YMTX” Initiated dosing in the Phase 1b part of our MAD trial of YMTX-7739 in patie...
Yumanity recently became public through a reverse merger with Proteostasis Therapeutics, a company I've previously covered. Yumanity has a new approach to tackling neurodegenerative disorders by targeting the build-up of misfolded proteins in the brain. Preliminary data has been p...
Yumanity Therapeutics (YMTX) has announced pre-clinical data to show the proof of concept of its lead asset YTX-7739 in a Parkinson’s disease ("PD") mouse model.YTX-7739 is a small molecule investigational therapy that can penetrate the blood-brain barrier and inhibit the act...
YTX-7739 demonstrates pharmacological, physiological, and behavioral pre-clinical proof of concept in in vivo model Study presented at AD/PD™ 2021 BOSTON, March 09, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical...
BOSTON, March 02, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., P...
Yumanity Therapeutics (YMTX) announces that dosing has started in its Phase 1b trial of YTX-7739 in patients with Parkinson’s Disease with preliminary results expected by mid 2021.YTX-7739, Yumanity's lead clinical-stage program, is designed to penetrate the blood-brain barri...
Results reported of the single ascending dose study in healthy volunteers Enrollment completed of the multiple ascending dose study in healthy volunteers; results expected by end of Q1 2021 Dosing initiated in a Phase 1b trial in patients with Parkinson’s Disease;...
BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Paulash Mohsen, Chief Business ...